Omada Health has released study results on weight loss among members of its GLP-1 program. Investing.com has the report with the details.
Recap by typeshit. Full story at Investing.com.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
The supplement ingredient is pitched by the company as a non-stimulant for cognition. Human trials only start in December 2026, with larger studies planned for 2027.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
Loading…